Login to Your Account



Vasopharm Gets $7M to Prep For Pivotal Brain Injury Trial

By Cormac Sheridan
Staff Writer

Wednesday, June 26, 2013
Vasopharm GmbH raised €5 million (US$6.5 million) in new investment to fund preparations for a Phase III trial of VAS203, an allosteric inhibitor of nitric oxide (NO) synthase in development for treating traumatic brain injury (TBI).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription